EHN omits articles about vaccination-autism findings

[Guest guest]

Environmental Health News provides a useful service but generally fails

to present news or scientific articles implicating vaccinations as

etiologically significant for at least some cases of autism. Instead,

EHN announces many articles that either " clear " vaccinations or turn

attention away from vaccinations. A few minutes ago, EHN's search

function indicated that EHN has not indexed the study presented herein

below. If you would like to help EHN know about the study, go to the

first link herein and enter at least the article's title and subsequent

three lines (including the Pubmed link).

//

Environmental Health News - article suggestions

http://www.environmentalhealthnews.org/email_submission.html

Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?

Tomljenovic L, Shaw CA.

J Inorg Biochem. 2011 Nov;105(11):1489-99.

http://www.ncbi.nlm.nih.gov/pubmed/22099159

Autism spectrum disorders (ASD) are serious multisystem developmental

disorders and an urgent global public health concern. Dysfunctional

immunity and impaired brain function are core deficits in ASD. Aluminum

(Al), the most commonly used vaccine adjuvant, is a demonstrated

neurotoxin and a strong immune stimulator. Hence, adjuvant Al has the

potential to induce neuroimmune disorders. When assessing adjuvant

toxicity in children, two key points ought to be considered: (i)

children should not be viewed as " small adults " as their unique

physiology makes them much more vulnerable to toxic insults; and (ii) if

exposure to Al from only few vaccines can lead to cognitive impairment

and autoimmunity in adults, is it unreasonable to question whether the

current pediatric schedules, often containing 18 Al adjuvanted vaccines,

are safe for children? By applying Hill's criteria for establishing

causality between exposure and outcome we investigated whether exposure

to Al from vaccines could be contributing to the rise in ASD prevalence

in the Western world. Our results show that: (i) children from countries

with the highest ASD prevalence appear to have the highest exposure to

Al from vaccines; (ii) the increase in exposure to Al adjuvants

significantly correlates with the increase in ASD prevalence in the

United States observed over the last two decades (Pearson r=0.92,

p<0.0001); and (iii) a significant correlation exists between the

amounts of Al administered to preschool children and the current

prevalence of ASD in seven Western countries, particularly at 3-4 months

of age (Pearson r=0.89-0.94, p=0.0018-0.0248). The application of the

Hill's criteria to these data indicates that the correlation between Al

in vaccines and ASD may be causal. Because children represent a fraction

of the population most at risk for complications following exposure to

Al, a more rigorous evaluation of Al adjuvant safety seems warranted.